Proactive Investors
20 Oct 2026, 02:21 UTC · 2h ago
Impact · against what's priced in
Anteris Technologies gains a recruitment catalyst for its PARADIGM trial by expanding into Germany, Europe's largest TAVR market. While the trial design is standard, the ability to accelerate the enrollment of 1,000 patients reduces execution risk for the pivotal study.
No priced-in read yet
What the story claims
2 claims · scored −1 bearish … +1 bullish · 1 new · 1 priced in
Anteris Technologies has secured full German regulatory clearance from the Federal Institute for Drugs and Medical Devices to expand its PARADIGM trial into Germany.
Newpublished 20 Oct 2026
So whatAccess to Europe's largest TAVR market likely accelerates the recruitment of the 1,000 patients needed for the All Comers Randomized Cohort.
More positive than 81% of claims this week
Continue reading
5 related stories
Securing German regulatory clearance provides access to high-volume structural heart centers, which is expected to accelerate the recruitment of the 1,000 patients required for the PARADIGM trial's Randomized Cohort.
Read from the article alone
No priced-in read yet
The mention of Wayne Paterson in relation to Admedus is tangential to the core clinical progress of the DurAVR valve and does not provide material fundamental updates.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
The PARADIGM trial will evaluate the safety and effectiveness of the DurAVR valve against commercial devices using a primary composite endpoint of all-cause mortality, stroke, and cardiovascular hospitalisation at one year.
Priced indescription of trial design
More positive than 58% of claims this week
Which stocks this story touches
More positive than 91% of ticker scores this week
The company received full German regulatory clearance for its pivotal PARADIGM trial, enabling recruitment in a major market.
More positive than 64% of ticker scores this week
Positive mention regarding the hospital discharge of the first patient following a clinical surgical aortic valve procedure.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Proactive Investors
15h ago
—
No price for AHZ right now — the quote feed didn't answer.
AHZ chart →—
AVR hasn't traded since this ran. Last close $6.18 (Oct 19); the reaction starts at the next open.
AVR chart →
